LinusBio vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
LinusBio is a precision medicine company using AI-powered exposome sequencing of hair samples to detect environmental and genetic disease risk factors; focuses on early autism detection; spun out of MIT; raised $12.5M in Series A funding.
About
LinusBio is a precision medicine and diagnostics company founded by Manish Arora and headquartered in New York, with roots in research at the Icahn School of Medicine at Mount Sinai and MIT. The company has developed a proprietary technology platform called exposome sequencing — a method of analyzing biological samples, primarily hair, to reconstruct a detailed timeline of environmental exposures and biological changes over months or years. This approach enables early detection of disease risk factors by reading both genetic and environmental signals simultaneously.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.